Panbela Therapeutics (PBLA) Competitors $0.25 0.00 (-0.20%) As of 05/20/2025 02:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock PBLA vs. ATNF, APLM, FRTX, ENSC, AEON, SNOA, APM, KLTO, DRMA, and TTNPShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include 180 Life Sciences (ATNF), Apollomics (APLM), Fresh Tracks Therapeutics (FRTX), Ensysce Biosciences (ENSC), AEON Biopharma (AEON), Sonoma Pharmaceuticals (SNOA), Aptorum Group (APM), Klotho Neurosciences (KLTO), Dermata Therapeutics (DRMA), and Titan Pharmaceuticals (TTNP). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. 180 Life Sciences Apollomics Fresh Tracks Therapeutics Ensysce Biosciences AEON Biopharma Sonoma Pharmaceuticals Aptorum Group Klotho Neurosciences Dermata Therapeutics Titan Pharmaceuticals 180 Life Sciences (NASDAQ:ATNF) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability. Does the media favor ATNF or PBLA? In the previous week, 180 Life Sciences had 1 more articles in the media than Panbela Therapeutics. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for Panbela Therapeutics. 180 Life Sciences' average media sentiment score of 1.38 beat Panbela Therapeutics' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Positive Panbela Therapeutics Neutral Is ATNF or PBLA more profitable? Panbela Therapeutics' return on equity of 0.00% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -558.93% -54.10% Panbela Therapeutics N/A N/A -302.61% Which has preferable earnings & valuation, ATNF or PBLA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$19.93MN/AN/APanbela TherapeuticsN/AN/A-$25.26M-$71.130.00 Do institutionals & insiders have more ownership in ATNF or PBLA? 4.1% of 180 Life Sciences shares are held by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are held by institutional investors. 0.2% of 180 Life Sciences shares are held by company insiders. Comparatively, 0.0% of Panbela Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor ATNF or PBLA? Panbela Therapeutics received 16 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 62.07% of users gave Panbela Therapeutics an outperform vote while only 16.67% of users gave 180 Life Sciences an outperform vote. CompanyUnderperformOutperform180 Life SciencesOutperform Votes216.67%Underperform Votes1083.33% Panbela TherapeuticsOutperform Votes1862.07% Underperform Votes1137.93% Do analysts prefer ATNF or PBLA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Panbela Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, ATNF or PBLA? 180 Life Sciences has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. SummaryPanbela Therapeutics beats 180 Life Sciences on 6 of the 11 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20M$6.54B$5.42B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio0.009.1426.7820.05Price / SalesN/A255.59395.49116.44Price / CashN/A65.8538.2534.62Price / Book-0.016.546.874.61Net Income-$25.26M$143.51M$3.22B$248.19M7 Day Performance-17.90%5.60%5.69%2.56%1 Month Performance-23.34%10.06%12.66%16.18%1 Year Performance-42.05%-0.86%18.01%8.16% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela TherapeuticsN/A$0.25-0.2%N/A-38.4%$1.20MN/A0.006Upcoming EarningsGap DownATNF180 Life SciencesN/A$1.10+0.9%N/A-24.8%$5.71MN/A0.007Earnings ReportGap UpAPLMApollomicsN/A$5.14-9.5%N/A-83.2%$5.67M$1.22M0.0045Positive NewsGap DownFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+2.0%$5.59M$10.06M-0.6620ENSCEnsysce Biosciences0.2419 of 5 stars$2.19+0.9%N/A-78.2%$5.19M$2.23M-0.0810AEONAEON Biopharma1.8472 of 5 stars$0.49+3.9%$360.00+73,070.7%-99.6%$5.18MN/A2.735SNOASonoma Pharmaceuticals0.2329 of 5 stars$3.17+0.6%N/A+1,349.3%$5.09M$13.97M-0.79180News CoveragePositive NewsGap UpAPMAptorum Group0.3448 of 5 stars$0.93+7.9%N/A-81.2%$4.97M$430,000.000.0030Positive NewsKLTOKlotho NeurosciencesN/A$0.17+5.0%N/AN/A$4.89MN/A0.00N/ANews CoverageEarnings ReportGap DownHigh Trading VolumeDRMADermata Therapeutics1.5167 of 5 stars$0.79-2.0%$6.00+655.7%-78.5%$4.79MN/A-0.058Positive NewsEarnings ReportTTNPTitan Pharmaceuticals0.7219 of 5 stars$5.23+2.8%N/A-32.6%$4.78M$180,000.00-1.0010Earnings ReportAnalyst Forecast Related Companies and Tools Related Companies 180 Life Sciences Competitors Apollomics Competitors Fresh Tracks Therapeutics Competitors Ensysce Biosciences Competitors AEON Biopharma Competitors Sonoma Pharmaceuticals Competitors Aptorum Group Competitors Klotho Neurosciences Competitors Dermata Therapeutics Competitors Titan Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
